Drugs / Placental Mesenchymal Stem Cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04652908 | Jun 2021 → Mar 2027 expected | myelomeningocele | University of California, Davis | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Placental Mesenchymal Stem Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04652908 ↗ |
| Modality | Cell therapy | “Live placenta-derived mesenchymal stem cells (PMSCs) seeded on an extracellular matrix have shown promise in rescuing neurological function in the fetal ovine model of myelomeningocele.” PMID 41763744 ↗ Feb 2026 |
| Route | Topical | “In-utero repair of the myelomeningocele was conducted with a single dose of topically applied allogeneic human PMSCs seeded on an extracellular matrix” PMID 41763744 ↗ Feb 2026 |